Systemic inflammation response index correlates with survival and predicts oncological outcome of resected pancreatic cancer following neoadjuvant chemotherapy

• DOI: 10.1016/j.pan.2022.08.009
• Publication Date: 2022-08-28T06:05:47Z
• Authors: Ji Su Kim; Munseok Choi; Sung Hyun Kim; Ho Kyoung Hwang; Woo Jung Lee; Chang Moo Kang
• Keywords: Neoadjuvant Therapy

The Systemic Inflammation Response Index (SIRI) has been used to predict the prognosis of various cancers. This study examined SIRI as a prognostic factor in neoadjuvant setting and determined whether it changing after chemotherapy is related patient prognosis.Patients who underwent pancreatic surgery following for cancer were retrospectively analyzed. To establish cut-off values, SIRIpre-neoadjuvant, SIRIpost-neoadjuvant, SIRIquotient (SIRIpost-neoadjuvant/SIRIpre-neoadjuvant) calculated significant values statistically examine their effects on survival rate.The included 160 patients. Values SIRIpost-neoadjuvant ≥ 0.8710 <0.9516 affected (hazard ratio [HR], 1.948; 95% confidence interval [CI], 1.210-3.135; ∗∗P = 0.006; HR, 1.548; CI, 1.041-2.302; 0.031). Disease-free differed significantly at < (P 0.0303). Overall between ≥0.9516 0.0368).SIRI can patients with ductal adenocarcinoma resection chemotherapy. Preoperative value was correlated disease-free survival, while changes overall survival.